drugset / Trial / NCT06048588
YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis
RandomizedParallel-groupTriple-blindTreatment
Summary
This study consists of two parts. The SAD and MAD of part I are a randomized, double-blind, placebo-controlled, single and multiple ascending dose study in healthy adult subjects. The MAD expansion cohort of part I is single arm and multipal ascending dose in heallthy subjects. Part II (phase Ib/IIa) is a multicenter, randomized, controlled, open label, multiple ascending dose study in patients with coronary atherosclerosis.
Timeline
- Start
- 2023-10-08
- Primary completion
- 2025-04-27
- Completion
- 2025-04-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rosuvastatin | Small molecule | 10 mg | Oral |
| Subject | YN001 | Unknown | 5 mg | Intravenous |
| Subject | YN001 | Unknown | 10 mg | Intravenous |
| Subject | YN001 | Unknown | 40 mg | Intravenous |
| Subject | YN001 | Unknown | 120 mg | Intravenous |